Clinical Trials
Department of Ophthalmology physician investigators are currently involved in a number of projects, encompassing a wide range of ophthalmologic specialties, including vitreoretinal disorders, glaucoma, corneal diseases and eye pathology.
Future plans include participation in more and varied clinical trials, with additional focus on refractive surgical interventions and treatments for uveitis as well as continued work in the specialty areas listed above. Our goal is to continue to offer research opportunities that will provide innovative treatments as well as explore broader disease processes.
Browse our active clinical trials below, and visit the Clinical Trials Frequently Asked Questions page for more information.
WATCH THIS VIDEO
Meet Dustin French, PhD, Associate Professor of Ophthalmology at Northwestern.
| Trials |
|---|
Eye Donor ProgramThe eye donor program is designed to contribute to our understanding of diseases of the eye. Patients will be asked permission to have their eyes donated for scientific evaluation at the time of the death of the patient. Donated eyes will be studied at the eye pathology lab of the … The eye donor program is designed to contribute to our understanding of diseases of the eye. Patients will be asked permission to have their eyes donated for scientific evaluation at the time of the death of the patient. Donated eyes will be studied at the eye pathology lab of the department of ophthalmology. Laboratory findings will be correlated and compared to the clinical findings observed in the same patients prior to their death. STU00017021 |
A Natural History Observation and Registry Study of Macular Telangiectasia Type 2: The MACTEL StudySince 2005, a group of scientists and clinicians from around the world have identified and are studying hundreds of persons with MacTel Type 2. Progress has been made to find ways to help prevent the condition from developing and to find potential treatment(s) but more work is needed. Special … Since 2005, a group of scientists and clinicians from around the world have identified and are studying hundreds of persons with MacTel Type 2. Progress has been made to find ways to help prevent the condition from developing and to find potential treatment(s) but more work is needed. Special scientists (geneticists) are working to understand if this disorder is inherited (passed down from your parents) and basic scientists are working to understand what happens to the eye tissue inside a MacTel eye. The purpose of this study is to identify persons with MacTel Type 2, and their affected family members to create a Registry of persons with MacTel Type 2. This Registry will be used to study participants with MacTel Type 2 now and may be used in the future to identify persons to be in a study that may help find a way to prevent or treat this eye condition. We also wish to keep in contact with persons who have told by their MacTel doctor that they have MacTel Type 2. In this document, the word “affected” means that it has been confirmed that you have MacTel Type 2. These persons may also be referred to as “Probands” when they are the first person in the family to be diagnosed with the disorder. “Unaffected” means that at this time, there is no evidence of MacTel Type 2. |
Evaluating Fenofibrate for Prevention of Diabetic Retinopathy WorseningEvaluating Fenofibrate for prevention of DR worsening- Screening visits then 2 visits per year for 4 years. Mild to Moderate NPDR Vision 20/25 or better No prior treatment for DME or DR NCT04661358 STU00214531 |
COASTPrimary SLT provides better clinical outcomes, fewer side effects, obviation of the need for daily self-dosing, and is cost-effective compared to topical medications. The recent publication of the LiGHT (Laser in Glaucoma and Ocular Hypertension) trial1 is likely to drive an overdue paradigm shift from our current medications-… Primary SLT provides better clinical outcomes, fewer side effects, obviation of the need for daily self-dosing, and is cost-effective compared to topical medications. The recent publication of the LiGHT (Laser in Glaucoma and Ocular Hypertension) trial1 is likely to drive an overdue paradigm shift from our current medications-first approach to an SLT-first practice pattern in the management of primary open-angle glaucoma (POAG). The overall goal of the study is to identify the optimal application of SLT therapy to provide maximal medication-free survival in trial participants with mild-moderate POAG or high-risk OHT. The optimal energy and repeat interval for SLT have not been established. The trabecular meshwork (TM) undergoes ongoing cumulative damage from both the underlying glaucoma process and from SLT.2-5 Low energy SLT may cause less TM damage and extend TM responsivity to subsequent SLT treatments, thus extending medication-free survival. Repeated annually to maintain TM cell health (rather than delaying repeat SLT until TM cells become dysfunctional and IOP rises) may further extend medication-free survival. 1. Age 18 or older and in good health 2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes): a. High-risk ocular hypertension (OHT): IOP > 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of >0.2 between eyes) [enrollment of trial participants with High-risk OHT will be capped at 25% of total enrollment] b. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° <15 dB (see figure on next page) c. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points <15 dB or mean deviation -12.0 dB or better with 1 central 5° points <15 dB (see figure on next page). 3. Each eye with BCVA 20/200 (UK 6/60) or better NCT04967989 STU00215448 |
IMVT-1401-3201Brief Summary: To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24. Participants must meet all the following criteria to be eligible for inclusion in the study: -Are ≥ 18 years of age at screening -Have a clinical diagnosis of TED associated with onset of active TED within 12 months prior to screening active - Moderate to severe TED. -Are euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism. NCT05517421 STU00219951 |
RGN-NK-302To compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
NCT05555589 STU00220018 |